Monoprost Duo (Latanoprost, Timolol)

Latanoprost, a prostaglandin analog, increases uveoscleral outflow of aqueous humor, while timolol, a non‑selective beta‑blocker, reduces aqueous humor production by blocking β‑adrenergic receptors in the ciliary body. The dual mechanism results in a net decrease in intra‑ocular pressure.

The dosing regimen for Monoprost Duo is determined by the prescribing ophthalmologist based on the individual patient's condition, response, and tolerance. Typically, one drop is instilled in the affected eye(s) once daily, but the exact schedule should follow the prescriber’s instructions.

Safety data for Monoprost Duo in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any potential risk to the fetus or infant, and the decision should be made by the treating physician in consultation with the patient.

To order Monoprost Duo, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request trade or institutional credentials before providing pricing, availability, shipping details and any necessary import documentation.

Monoprost Duo combines two mechanisms—enhanced outflow and reduced production—offering greater IOP reduction than single‑agent prostaglandin analogs or beta‑blockers alone. Compared with other combination drops, it provides a convenient once‑daily regimen, but choice of therapy should be individualized based on efficacy, tolerability and patient comorbidities.

Monoprost Duo should be stored at room temperature, below 25 °C, in the original container. Keep the bottle tightly closed, protect it from light and moisture, and discard any solution that appears discolored or contains particles.

The product is administered as an ocular drop. The patient should wash hands, tilt the head back, pull down the lower eyelid to create a small pocket, and place one drop into the conjunctival sac of each prescribed eye. Avoid touching the tip of the bottle to the eye or any surface.

Serious risks include severe allergic reactions, persistent ocular pain or inflammation, sudden loss of vision, systemic bradycardia, and exacerbation of asthma or chronic obstructive pulmonary disease. Patients should seek immediate medical attention if they experience any of these symptoms.

Monoprost Duo is contraindicated in patients with known hypersensitivity to latanoprost, timolol or any excipients, and in those with active ocular infections or inflammation. It should also be avoided in individuals with severe asthma, COPD, bradycardia, or uncontrolled heart failure unless specifically advised by a physician.